한글목차

세계 수두 백신 시장의 미래는 병원 및 진료소 시장에서의 기회로 인해 유망한 것으로 보입니다. 세계 수두 백신 시장은 2025-2031년 5.8%의 연평균 복합 성장률(CAGR)로 2031년까지 약 49억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 세계 예방접종 프로그램 증가, 수두 백신 사용에 대한 대중의 인식 증가, 예방접종 프로그램에 대한 정부의 기여도 증가입니다.

• Lucintel의 예측에 따르면 용도별로는 대상포진이 예측 기간 중 가장 높은 성장세를 보일 것으로 예상됩니다.
• 최종 용도별로는 병원이 예측 기간 중 높은 성장을 보일 것으로 예상됩니다.
• 지역별로는 북미가 백신 접종 프로그램이 확립되어 있고, 인구 증가에 따른 백신 접종 수요가 증가함에 따라 북미가 계속해서 가장 규모가 큰 지역이 될 것으로 보입니다.

수두 백신 시장의 전략적 성장 기회

수두 백신 시장의 성장을 가속화하는 요인은 기술 개발, 인지도 향상, 주요 부문의 예방접종 캠페인 증가입니다.

• 신규 시장 : 신규 시장은 수두 백신 접종 프로그램을 확대하는 데 있으며, 많은 성장 기회를 제공합니다. 시장 점유율 확대와 전 세계 환자 수 감소를 위한 유리한 조건의 창출은 이들 지역의 접근성 및 가격 개선을 통해 달성할 수 있을 것입니다.
• 혼합백신 개발: 수두를 포함한 혼합백신에 대한 투자는 예방접종 일정을 간소화하고, 예방접종 순응도를 높일 수 있습니다. 이 전략은 면역을 통합하고 백신 접종 과정을 단순화하여 마케팅 효과를 높일 수 있습니다.
• 백신 제제 강화: 백신의 부작용이 적고, 면역 기간이 길고, 더 나은 새로운 제제 개발은 성장 기회가 있습니다. 이러한 개발은 수두 백신의 수용을 촉진하고 사용량을 증가시킬 것으로 예상됩니다.
• 정기 예방접종 일정에 포함: 수두 예방접종을 소아기 예방접종 계획에 포함시킴으로써 수두 예방접종률을 유지하고 수두 발병을 예방할 수 있습니다. 이 방법은 예방접종률을 높이고 전체 공중보건을 개선하는 데 도움이 될 수 있습니다.
• 공중보건 인식 개선 프로그램 및 교육: 공중보건과 수두 예방접종의 중요성에 대한 인식에 초점을 맞추면 성장을 가속할 수 있습니다. 예방접종의 위험과 이점을 알리는 교육 프로그램은 백신 접종률과 접종률을 높이는 데 도움이 될 수 있습니다.

이러한 기회는 접근성 개선, 백신 기술 발전, 공중 보건 분야의 잠재력 확대를 통해 수두 백신 시장을 형성하고 있습니다.

수두 백신 시장 성장 촉진요인 및 과제

수두 백신 시장의 기업은 기술 발전, 경제 요인, 규제 등 다양한 영향, 촉진요인 및 과제에 노출되어 있습니다. 이러한 요소를 이해하는 것은 시장 상황을 탐색하는 데 필수적입니다.

수두 백신 시장을 촉진하는 요인은 다음과 같습니다. :

• 기술 발전: 백신 접종 기술은 새로운 제형과 조합 등 큰 변화를 겪으며 매출 증가를 견인하고 있습니다. 이러한 개선은 백신의 효율성과 안전성을 향상시켜 백신 접종률을 높이고 공중보건을 개선하는 데 기여하고 있습니다.
• 대중의 인식 향상: 일반 대중의 인식이 높아지면서 수두 예방접종에 대한 수요가 증가하고 있습니다. 그 결과, 공중보건 캠페인과 교육적 개입을 통해 백신 접종률이 향상되어 수두 환자가 감소하고 있습니다.
• 백신 접근성 확대: 시장 성장의 원동력은 수두 백신에 대한 접근성이 부족한 신흥 시장에서 수두 백신에 대한 접근성 확대에 있습니다. 수두 백신을 쉽게 접종할 수 있고 저렴한 가격의 백신이 등장하면서 전 세계 수두 발병률 감소와 예방접종률 향상에 기여했습니다.

수두 백신 시장이 해결해야 할 과제는 다음과 같습니다. :

• 규제적 과제: 규제적 과제: 백신 제품의 인증 및 안전성에 대한 엄격한 가이드라인을 충족하는 것이 종종 장애물이 됩니다. 시장 진입 및 제품 개발에 필요한 규정 준수는 일정과 지출에 영향을 미칩니다.
• 경제적 제약: 경제적 요인은 경제 상황의 변화에 따른 백신 제조 비용의 변동과 가격 경쟁력 등 시장 역학에 영향을 미칠 수 있습니다. 비용과 품질의 균형을 유지하는 것은 경쟁력 있는 사업 확장을 위해 중요합니다.

이러한 촉진요인 및 과제는 모두 제품 개발, 시장 개발, 규제 준수에 영향을 미치기 때문에 수두 백신 시장을 형성합니다.

목차

제1장 개요

제2장 세계의 수두 백신 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 수두 백신 시장 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 수두 백신 시장 : 제품 유형별
  • 1가 수두 백신
  • 혼합 수두 백신
• 세계의 수두 백신 시장 : 용도별
  • 볼거리
  • 홍역
  • 풍진
  • 수두 예방 접종
  • 대상포진
  • 면역
  • 수두 백신 접종
• 세계의 수두 백신 시장 : 최종 용도별
  • 병원
  • 클리닉
  • 기타

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 세계의 수두 백신 시장 : 지역별
• 북미의 수두 백신 시장
• 유럽의 수두 백신 시장
• 아시아태평양의 수두 백신 시장
• 기타 지역의 수두 백신 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 수두 백신 시장의 성장 기회 : 제품 유형별
  • 세계의 수두 백신 시장의 성장 기회 : 용도별
  • 세계의 수두 백신 시장의 성장 기회 : 최종 용도별
  • 세계의 수두 백신 시장의 성장 기회 : 지역별
• 세계의 수두 백신 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 수두 백신 시장의 생산능력 확대
  • 세계의 수두 백신 시장에서의 기업인수합병(M&A), 합병사업
  • 인증과 라이선싱

제7장 주요 기업의 개요

• Bio-Med
• GlaxoSmithKline
• Emcure Pharmaceuticals
• Novo Medi Services
• Sanofi
• Takeda Pharmaceutical
• Changchun BCHT Biotechnology
• Green Cross Holdings
• Merck
• Mitsubishi Chemical Holdings

영문목차

The future of the global chickenpox vaccine market looks promising with opportunities in the hospital and clinic markets. The global chickenpox vaccine market is expected to reach an estimated $4.9 billion by 2031 with a CAGR of 5.8% from 2025 to 2031. The major drivers for this market are the increasing number of vaccination programs worldwide, the rising public awareness of the use of chickenpox vaccines, and the growing government contribution to immunization programs.

• Lucintel forecasts that, within the application category, herpes zoster is expected to witness the highest growth over the forecast period.
• Within the end-use category, the hospital is expected to witness higher growth over the forecast period.
• In terms of regions, North America will remain the largest region due to the presence of a well-established vaccination program and the growing demand for vaccine coverage with an expanding population in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Chickenpox Vaccine Market

The market for chickenpox vaccines is witnessing multiple emerging trends that are shaping future vaccination efforts and public health strategies.

• More Emphasis on Combination Vaccines: There is growing interest in combination vaccines that include chickenpox along with other vaccines. This simplification of vaccination schedules and the greater likelihood of adherence will increase overall immunization rates.
• Access to Emerging Markets: Global coverage has increased due to efforts to extend vaccination programs to emerging markets. Better accessibility and affordability have led to higher rates of immunization and fewer cases of chickenpox in previously underserved areas.
• Better Vaccine Formulations: Improvements in vaccine formulations are resulting in more effective vaccines with longer-lasting immunity and fewer side effects. It is expected that these improvements will enhance the performance and safety of vaccines, thus increasing their acceptance and use by a wider population.
• Incorporation into Routine Immunization Schedules: Several countries are incorporating chickenpox vaccination into routine immunization schedules. The intention behind this trend is to ensure uniformity across the board, reducing cases of chickenpox that could lead to outbreaks.
• Emphasis on Public Health Campaigns: Public health campaigns have shifted their focus toward creating awareness about the need for chickenpox vaccination. These campaigns contribute to enlightening people, addressing vaccine hesitancy, and increasing vaccination levels.

These trends are revamping the chickenpox vaccine market through improved vaccine technology, broader access, and heightened public awareness.

Recent Developments in the Chickenpox Vaccine Market

The chickenpox vaccine market is witnessing several key developments that reflect advancements in vaccine technology, increased access, and improved public health initiatives.

• Introduction of Combination Vaccines: New combination vaccines that include chickenpox alongside other childhood vaccines are being introduced. The creation of these new combination vaccines will streamline vaccination schedules, improve compliance rates, and enhance overall vaccination coverage.
• Expansion of Vaccine Access: Initiatives are underway to increase chickenpox vaccine accessibility in underserved and rural areas. This move results from governmental measures and public health campaigns aimed at enhancing immunization coverage while minimizing outbreaks.
• Advancements in Vaccine Formulations: Recent advances in vaccine formulations result in better vaccines with greater efficacy, prolonged protection, and fewer side effects. These enhancements also contribute to improved vaccine performance and increased acceptability.
• Enhanced Public Health Campaigns: Public health campaigns are on the rise that focus on sensitizing the general population about the importance of chickenpox vaccination. Awareness programs like this help educate people, combat hesitancy about vaccinations by providing information, and boost vaccination rates.
• Integration into Routine Immunization: Several countries are incorporating chickenpox vaccination into their routine immunization schedules. The aim is to ensure universal coverage, thus reducing cases of chickenpox and preventing outbreaks.

These developments are advancing the chickenpox vaccine market by improving vaccine technology, increasing access, and enhancing public health efforts.

Strategic Growth Opportunities for Chickenpox Vaccine Market

Accelerating the growth of the chickenpox vaccine market is the development of technology, growing awareness, and increased immunization campaigns in key sectors.

• New Markets: New markets offer plenty of opportunities for growth in expanding chickenpox vaccination programs. Creating favorable conditions for a larger market share and a decrease in overall global cases will be achieved through improvements in accessibility and affordability in these regions.
• Combined Vaccine Development: Investing in combination vaccines that include varicella will simplify immunization schedules and foster compliance. This strategy can improve marketing appeal by consolidating immunities and simplifying the vaccination process.
• Enhanced Vaccine Formulation: Growth opportunities exist in developing better and new formulations with fewer side effects and longer immunity periods for vaccines. It is expected that such developments will promote acceptance and thus increase the use of chickenpox vaccines.
• Embedding Into Routine Immunization Schedules: By integrating chickenpox vaccination into planned childhood immunizations, children's coverage can be maintained, thereby averting outbreaks. This method can lead to higher rates of vaccination and better overall public health.
• Public Health Awareness Programs and Education: Focusing on public health and awareness about the importance of chickenpox vaccination has the potential to drive growth. Education programs aimed at informing people about the risks and benefits of immunizations will lead to increased uptake and coverage for vaccines.

These opportunities have shaped the chickenpox vaccine market by increasing its reach through access improvements, technological advances in vaccines, and expansion of possibilities within public health areas.

Chickenpox Vaccine Market Driver and Challenges

Players in the chickenpox vaccine market are subject to various influences, drivers, and challenges such as technological advancements, economic factors, and regulations. Understanding these elements is vital for navigating the market landscape.

The factors driving the chickenpox vaccine market include:

• Technological Advancements: Vaccination technologies have undergone significant changes, such as newer formulas and combinations, which have boosted sales. These improvements heighten vaccine efficiency and safety, leading to higher acceptance rates and better public health outcomes.
• Increased Public Awareness: There is an increasing demand for chickenpox vaccinations due to heightened awareness among the public. This has resulted in increased vaccination rates through public health campaigns and educational interventions that have reduced cases of chickenpox.
• Expansion of Vaccine Access: The market's growth has been driven by attempts to expand access to chickenpox vaccines in underserved and emerging markets. Improved availability and affordability have led to a decline in the global incidence of chickenpox and enhanced immunization coverage.

Challenges in the chickenpox vaccine market include:

• Regulatory Challenges: Issues arising from meeting strict guidelines governing accreditation for vaccine products and safety often pose obstacles. Compliance with rules needed for market entry or product development affects timelines and expenditures.
• Economic Constraints: Economic factors can influence market dynamics, such as fluctuating vaccine production costs and affordability due to changing economic conditions. Maintaining a cost-quality balance is important for competitive business expansion.

All these drivers and challenges shape the chickenpox vaccine market because they affect product development, market growth, and regulatory compliance.

List of Chickenpox Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies chickenpox vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the chickenpox vaccine companies profiled in this report include-

• Bio-Med
• GlaxoSmithKline
• Emcure Pharmaceuticals
• Novo Medi Services
• Sanofi
• Takeda Pharmaceutical
• Changchun BCHT Biotechnology
• Green Cross Holdings
• Merck
• Mitsubishi Chemical Holdings

Chickenpox Vaccine by Segment

The study includes a forecast for the global chickenpox vaccine market by product type, application, end use, and region.

Chickenpox Vaccine Market by Product Type [Analysis by Value from 2019 to 2031]:

• Monovalent Varicella Vaccine
• Combination Varicella Vaccine

Chickenpox Vaccine Market by Application [Analysis by Value from 2019 to 2031]:

• Mumps
• Measles
• Rubella
• Varicella Immunization
• Herpes Zoster
• Immunization
• Chickenpox Vaccination

Chickenpox Vaccine Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Clinics
• Others

Chickenpox Vaccine Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Chickenpox Vaccine Market

The market for chickenpox vaccines is changing as vaccine technology advances, global vaccination campaigns increase, and awareness of the prevention of chickenpox grows. Recent developments indicate better vaccine formulations, more accessible vaccines, and new public health initiatives aimed at reducing the incidence of chickenpox and its complications.

• United States: In the U.S., there has been progress in varicella vaccines with updated versions that offer improved effectiveness and longer-lasting protection. Better school-based immunization programs and increased vaccine outreach efforts have led to higher vaccination rates and a decrease in outbreaks.
• China: The expansion of access to rural areas and underserved communities has been a key focus for China regarding the distribution of chickenpox vaccines. The government is investing in vaccination programs and public health education to enhance vaccination coverage against chickenpox and control outbreaks.
• Germany: Combination vaccines containing chickenpox and other childhood infections are now being used in Germany. The objective is to minimize the number of shots that children need to receive while increasing adherence. Additionally, Germany is improving its vaccination programs by introducing school mandates and public awareness campaigns.
• India: India's market for chickenpox vaccines is expanding due to an increase in low-cost vaccine availability. Public health campaigns are raising awareness about the significance of immunization, leading to increased uptake, particularly in remote areas where vaccination services are becoming accessible.
• Japan: Japan has made strides in developing better vaccines that provide improved immunity against varicella with fewer side effects. Additionally, Japan aims to include this vaccine in routine immunizations to keep all recipients protected from illness.

Features of the Global Chickenpox Vaccine Market

Market Size Estimates: Chickenpox vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Chickenpox vaccine market size by product type, application, end use, and region in terms of value ($B).

Regional Analysis: Chickenpox vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, applications, end uses, and regions for the chickenpox vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the chickenpox vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the chickenpox vaccine market by product type (monovalent varicella vaccine and combination varicella vaccine), application (mumps, measles, rubella, varicella immunization, herpes zoster, immunization, and chickenpox vaccination), end use (hospitals, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Chickenpox Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Chickenpox Vaccine Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Chickenpox Vaccine Market by Product Type
  • 3.3.1: Monovalent Varicella Vaccine
  • 3.3.2: Combination Varicella Vaccine
• 3.4: Global Chickenpox Vaccine Market by Application
  • 3.4.1: Mumps
  • 3.4.2: Measles
  • 3.4.3: Rubella
  • 3.4.4: Varicella Immunization
  • 3.4.5: Herpes Zoster
  • 3.4.6: Immunization
  • 3.4.7: Chickenpox Vaccination
• 3.5: Global Chickenpox Vaccine Market by End Use
  • 3.5.1: Hospitals
  • 3.5.2: Clinics
  • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Chickenpox Vaccine Market by Region
• 4.2: North American Chickenpox Vaccine Market
  • 4.2.1: North American Market by Application: Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization, and Chickenpox Vaccination
  • 4.2.2: North American Market by End Use: Hospitals, Clinics, and Others
• 4.3: European Chickenpox Vaccine Market
  • 4.3.1: European Market by Application: Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization, and Chickenpox Vaccination
  • 4.3.2: European Market by End Use: Hospitals, Clinics, and Others
• 4.4: APAC Chickenpox Vaccine Market
  • 4.4.1: APAC Market by Application: Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization, and Chickenpox Vaccination
  • 4.4.2: APAC Market by End Use: Hospitals, Clinics, and Others
• 4.5: ROW Chickenpox Vaccine Market
  • 4.5.1: ROW Market by Application: Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization, and Chickenpox Vaccination
  • 4.5.2: ROW Market by End Use: Hospitals, Clinics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Chickenpox Vaccine Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Chickenpox Vaccine Market by Application
  • 6.1.3: Growth Opportunities for the Global Chickenpox Vaccine Market by End Use
  • 6.1.4: Growth Opportunities for the Global Chickenpox Vaccine Market by Region
• 6.2: Emerging Trends in the Global Chickenpox Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Chickenpox Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Chickenpox Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Bio-Med
• 7.2: GlaxoSmithKline
• 7.3: Emcure Pharmaceuticals
• 7.4: Novo Medi Services
• 7.5: Sanofi
• 7.6: Takeda Pharmaceutical
• 7.7: Changchun BCHT Biotechnology
• 7.8: Green Cross Holdings
• 7.9: Merck
• 7.10: Mitsubishi Chemical Holdings